Vascular interventions are a promising application of Magnetic Particle Imaging enabling a high spatial and temporal resolution without using ionizing radiation. The possibility to visualize the vessels as well as the devices, especially at the same time using multi-contrast approaches, enables a higher accuracy for diagnosis and treatment of vascular diseases. Different techniques to make devices MPI visible have been introduced so far, such as varnish markings or filling of balloons. However, all approaches include challenges for in vivo applications, such as the stability of the varnishing or the visibility of tracer filled balloons in deflated state. In this contribution, we present for the first time a balloon catheter that is molded from a granulate incorporating nanoparticles and can be visualized sufficiently in MPI. Computed tomography is used to show the homogeneous distribution of particles within the material. Safety measurements confirm that the incorporation of nanoparticles has no negative effect on the balloon. A dynamic experiment is performed to show that the inflation as well as deflation of the balloon can be imaged with MPI.
Objective. The availability of magnetic nanoparticles (MNPs) with medical approval for human intervention is fundamental to the clinical translation of magnetic particle imaging (MPI). In this work, we thoroughly evaluate and compare the magnetic properties of an magnetic resonance imaging (MRI) approved tracer to validate its performance for MPI in future human trials. Approach. We analyze whether the recently approved MRI tracer Resotran is suitable for MPI. In addition, we compare Resotran with the previously approved and extensively studied tracer Resovist, with Ferrotran, which is currently in a clinical phase III study, and with the tailored MPI tracer Perimag. Main results. Initial magnetic particle spectroscopy (MPS) measurements indicate that Resotran exhibits performance characteristics akin to Resovist, but below Perimag. We provide data on four different tracers using dynamic light scattering, transmission electron microscopy, vibrating sample magnetometry measurements, MPS to derive hysteresis, point spread functions, and a serial dilution, as well as system matrix based MPI measurements on a preclinical scanner (Bruker 25/20 FF), including reconstructed images. Significance. Numerous approved MNPs used as tracers in MRI lack the necessary magnetic properties essential for robust signal generation in MPI. The process of obtaining medical approval for dedicated MPI tracers optimized for signal performance is an arduous and costly endeavor, often only justifiable for companies with a well-defined clinical business case. Resotran is an approved tracer that has become available in Europe for MRI. In this work, we study the eligibility of Resotran for MPI in an effort to pave the way for human MPI trials.
11 September 2014 in IEEE Transactions on Medical Imaging
The magnetic particle imaging (MPI) technology is a new imaging technique featuring an excellent possibility to detect iron oxide based nanoparticle accumulations in vivo. The excitation of the particles and in turn the signal generation in MPI are achieved by using oscillating magnetic fields. In order to realize a spatial encoding, a field-free point (FFP) is steered through the field of view (FOV). Such a positioning of the FFP can thereby be achieved by mechanical or electromagnetical movement. Conventionally, the data acquisition path is either a planar 2-D or a 3-D FFP trajectory. Assuming human applications, the size of the FOV sampled by such trajectories is strongly limited by heating of the body and by nerve stimulations. In this work, a new approach acquiring MPI data based on the axial elongation of a 2-D FFP trajectory is proposed. It is shown that such an elongation can be used as a data acquisition path to significantly increase the acquisition speed, with negligible loss of spatial resolution.
The purpose of this work was to develop instrument markers that are visible in both magnetic particle imaging (MPI) and magnetic resonance imaging (MRI). The instrument markers were based on two different magnetic nanoparticle types (synthesized in-house KLB and commercial Bayoxide E8706). Coatings containing one of both particle types were fabricated and measured with a magnetic particle spectrometer (MPS) to estimate their MPI performance. Coatings based on both particle types were then applied on a segment of a nonmetallic guidewire. Imaging experiments were conducted using a commercial, preclinical MPI scanner and a preclinical 1 tesla MRI system. MPI image reconstruction was performed based on system matrices measured with dried KLB and Bayoxide E8706 coatings. The bimodal markers were clearly visible in both methods. They caused circular signal voids in MRI and areas of high signal intensity in MPI. Both the signal voids as well as the areas of high signal intensity were larger than the real marker size. Images that were reconstructed with a Bayoxide E8706 system matrix did not show sufficient MPI signal. Instrument markers with bimodal visibility are essential for the perspective of monitoring cardiovascular interventions with MPI/MRI hybrid systems.
Magnetic particle imaging (MPI) is a promising imaging modality nearing clinical introduction. MPI's tracer‐based principle allows for highly sensitive background‐free imaging. Potential clinical applications include cardiovascular imaging and endovascular interventions. In principle, medical instruments are invisible in MPI due to the missing signal generation. Therefore, permanent marking technologies have been introduced. Additionally, temporary markers are of interest for follow‐up examinations after stent implantation to prevent artifacts during postinterventional stent lumen quantification. Consequently, medical instrument markers for MPI, based on biodegradable polylactic acid (PLA) and superparamagnetic iron‐oxide nanoparticles (SPIONs), are developed in this study. To investigate the markers, signal characteristics and degradation over time are studied for 28 d in a water bath at 37 °C. The samples are analyzed using a scale, micro‐CT, microscopy, magnetic particle spectroscopy (MPS), MPI, and vibrating sample magnetometry (VSM). A continuous mass decrease is detected (≈90% after 28 d), while MPS and MPI data show no loss of signal. VSM confirms that the markers’ mass reduction can be accounted for the degradation of PLA, while the SPIONs hardly detach from the coating. The introduced marking technology, with its degradation characteristics and signal behavior, is the basis for a variety of anticipated medical application scenarios.
Magnetic Particle Imaging (MPI) detects superparamagnetic nanoparticles, enabling bimodal contrast with MRI. Resovist®/Ferucarbotran, still used in research, has clinical safety compatibility but suboptimal MPI performance due to many small 5 nm SPIO cores. Magnetic fractionation can enrich larger cores, improving MPI signal and supporting cellular imaging applications. To enable bimodal MRI/MPI and assess in vivo extracellular vesicle (EV) labelling, we characterized the imaging sensitivity and cell-labelling performance of VivoTrax, a commercial formulation similar to Resovist®, and VivoTrax Plus, obtained by magnetic fractionation. VivoTrax Plus showed higher MRI transverse relaxivity and MPI sensitivity than VivoTrax, and both formulations displayed low toxicity toward adipose-derived stem cells (ASCs). VivoTrax Plus allowed MRI detection of small cell numbers, around 100 cells, in agarose phantoms with greater sensitivity than VivoTrax. However, EVs of 30–150 nm isolated from ASCs labelled with VivoTrax Plus did not retain SPIONs, whereas EVs from VivoTrax-labelled ASCs did. Preliminary in vivo experiments in SOD-G93A mice showed MRI-detectable signal voids in the brain after intranasal EV administration, suggesting EV migration to lesioned areas. Overall, magnetic fractionation improves SPION imaging sensitivity but may alter relevant biological properties.